Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13 Gastrointestinal 9 Other solid neoplasm 3 Gynecologic 3 Breast 3 Thoracic 2 Sarcoma 2 NET 1 Endocrine 1 CNS 1

Conditions

Interventions

Temozolomide 610 Radiotherapy 388 Bevacizumab 254 Magnetic Resonance Spectroscopy 203 Cyclophosphamide 177 Carboplatin 159 Radiosurgery 146 Etoposide 132 Radiation 121 Irinotecan 115 Vincristine 114 Cisplatin 102 Filgrastim 100 Specimen Handling 88 Nivolumab 87 pembrolizumab 82 Lomustine 81 Topotecan 73 Surgical Procedures, Operative 73 Doxorubicin 60 Melphalan 59 Carmustine 57 sargramostim 53 Radiotherapy, Intensity-Modulated 53 Isotretinoin 53 Peripheral Blood Stem Cell Transplantation 52 Granulocyte Colony-Stimulating Factor 50 Erlotinib Hydrochloride 50 Everolimus 48 Chemotherapy, Adjuvant 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × tivozanib × CNS × Clear all

NCT01846871 2019-01-08

Tivozanib for Recurrent Glioblastoma

Massachusetts General Hospital

Phase 2 Completed

10 enrolled 13 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡